Influencing Factors of Progression Free Survival(PFS) in Late Course Conformal Radiotherapy for ⅲ Stage Non-small Cell Lung Cancer 后程适形放疗治疗Ⅲ期非小细胞肺癌无进展生存(PFS)期影响因素分析
In this trial, the overall median progression free survival ( PFS ) was9.2 months with pazopanib and4.2 months with placebo. 在这个试验中,整体无进展生存(PFS)期(PFS)为9.2和4.2个月,帕唑帕尼与安慰剂个月。
The 1 - and 2-year local progression free survival ( LPFS ) rates were both 88.8 %. 1年、2年的无局部进展生存率(LPFS)均为88.8%。
The secondary endpoints included progression free survival ( PFS ), local control rate and acute toxicity. 次要终点包括总生存(OS)、局部控制率及药物急性毒性。
Follow up studies found that the expression of sPD-L1 was negatively correlated with clinical response. Lung cancer group with high sPD-L1 expression exhibited longer progression free survival ( PFS ) and higher 1-year survival rate, indicating better prognosis. 临床随访研究发现,肺癌患者血清sPD-L1表达水平和临床疗效呈负相关,在预后方面低表达sPD-L1组肺癌患者无进展生存(PFS)期更长、1年生存率更高,预后更好。